Adjuvant Therapies for Lung Cancers: New Directions
|
|
- Myra McKenzie
- 5 years ago
- Views:
Transcription
1 Adjuvant Therapies for Lung Cancers: New Directions Mark G Kris, MD Member and Attending Physician William and Joy Ruane Chair in Thoracic Oncology Memorial Sloan-Kettering Professor of Medicine, Weill Cornell Medical College New York, New York USA
2 New Directions for Adjuvant Therapies of Lung Cancers Disclosures Consultant/Trial Support: Pfizer, Genentech/Roche, Novartis, Clovis, Ariad Stock/Royalties: None
3 New Directions for Adjuvant Therapies of Lung Cancers Additional Disclosures I was born a medical oncologist but was raised by thoracic surgeons I am a chemotherapy guy who has gone molecular
4 Memorial Sloan-Kettering Thoracic Oncology Service Charles Rudin, MD, PhD Service Chief Mark G. Kris, MD Lee M. Krug, MD Naiyer A. Rizvi, MD Gregory J. Riely, MD, PhD Maria C. Pietanza, MD Paul K. Paik, MD Jamie Chaft, MD Marjorie Zauderer, MD Alexander E. Drilon, MD Helena A. Yu, MD Stephen Veach, MD Kenneth Ng, MD John Fiore, MD Stephanie Smith-Marrone, MD Afsheen Iqbal, MD Stefan Berger, MD Michael Fannuchi, MD
5 New Directions for Adjuvant Therapies of Lung Cancers Introduction All stages need more cures Eradicating metastases the goal EGFR as a target Results in patients with early stages Trials in progress and proposed Seizing the opportunities
6 Bending the survival curve in lung cancers Rudin Proc IASLC 2013
7 Do Good Prognosis Lung Cancers Exist? T Stage (all N0M0) Primary Size N 5 Year Survival Clinical Stage 5 Year Survival Pathological Stage T1a 2 cm % 77% T1b > 2-3 cm % 71% T2a > 3-5 cm % 58% T2b > 5-7 cm % 49% T2c > % 35% Rami-Porta J Thorac Oncol 2007
8 Prognostic Factors in Lung Cancers There are no good prognosis lung cancers 23% of patients with tumors less than 2 cm (Stage pt1an0m0) are dead at 5 years. All patients with breast cancer with this degree of risk are recommended additional therapy with primary treatment.
9
10 EGFR Mutations in Early Stage Lung Cancers Metastases: #1 Cause of Failure Rates of Systemic Failure by Disease Extent at Presentation - Local 80% - Regional 80% - Advanced 100%
11 NSCLC Adjuvant Trials Post 1995 Meta-Analysis Survival With Adjuvant Chemotherapy # Pts 5 yr (%) HR 95% CI p Meta JNCI 03; NEJM 04; NEJM 05; JCO 09; Lancet Oncol Meta
12
13
14
15 Strategies to Select Drugs for Use With Surgery in Early Stage Lung Cancers Driver mutations Histologic type Repair/Metabolism genotype Gene expression profiles Assess radiographic response in induction window of opportunity
16 Actionable Targets in Lung Adenocarcinomas Unknown 75% Unknown 60% EGFR KRAS Unknown 35% KRAS RET EGFR ROS1 MEK HER2 ALK MET PIK3CA Kris M et al. IASLC 2012 Targeted BRAF Therapies Conference
17 EGFR-mutant Lung Cancers Following the GIST Playbook Single driver mutation Sensitivity to kinase inhibitors Eventual acquired resistance Development of 2 nd site mutations Continued clinical benefit from kinase inhibitors after progression Survival benefit of adjuvant TKI
18 Adjuvant Imatinib in GIST Imatinib 1 Year vs 3 Years Recurrence-free survival Overall survival Joensuu NEJM 2012
19 SELECT* : A multicenter phase II trial of adjuvant erlotinib in 100 EGFR-mutant lung cancers Neal Proc ASCO 2012
20 Months on Erlotinib Duration of Erlotinib Treatment duration and dose reductions Reasons for discontinuation 1 Travel precluded participation 2 Diarrhea 3 Rash/Diarrhea 4 Diarrhea/fatigue 5 Prostate cancer radiotherapy 6 Patient preference 7 Rash 8 Disease progression 9 Patient preference 10 Rash
21 SELECT Overall Survival
22 MSK Patients with EGFR Mutant Lung Cancers Use of Adjuvant Gefitinib or Erlotinib Stage I-III with EGFR mutant lung cancers N=146 Exon 19 deletions 56% Exon 21: L858R (71) and L861Q (2) 44% Received adjuvant chemotherapy 30% Received adjuvant gefitinib (21) or erlotinib (32) 32% Median time on gefitinib or erlotinib (months) 16 (0.7 to 30) Janjigian J Thorac Oncol 2011
23 Disease Free Survival (%) Adjuvant Gefitinib and Erlotinib Impact on Disease Free Survival No adjuvant gefitinib/ erlotinib Adjuvant gefitinib/erlotinib Adjusted Hazard Ratio=0.53 (95%CI, ) p=0.06* Events: gefitinib/erlotinib 13(23%) no gefitinib/erlotinib 43(39%) Time (months) Number at Risk no G/E therapy 95 G/E therapy 51 Janjigian J Thorac Oncol 2011; 6:
24 Proportion Disease Free Surviving Proportion Overall Surviving MSK Patients with EGFR Mutant Lung Cancers Use of Adjuvant Gefitinib or Erlotinib DISEASE FREE SURVIVAL Adjuvant gefitinib/erlotinib OVERALL SURVIVAL No TKI no g/e, n=202 g/e, TKI n=56 adjusted HR: 0.48 (0.29, 0.80), p=0.005 Adjusted HR: 0.40, p=.005 No TKI no g/e, n=202 g/e, TKI n=56 Adjusted HR: 0.56 (0.27, 1.17), p=0.123 Adjusted HR: 0.56, p= Number at Risk No no TKI g/e 159 g/e 74 TKI Months Number at Risk No no TKI g/e 163 g/e 79 TKI Months D Angelo J Thorac Oncol 2012
25 No EGFR TKI Acquired Resistance in Patients Completing Adjuvant EGFR TKIs
26 EURECA Erlotinib Used as Adjuvant Therapy in REsected EGFR Mutant Lung Carcinomas Lung Cancer Mutation Consortium PI: Christopher Azzoli, MD Resected stage I-III EGFRmutation positive lung cancer with activating EGFR mutation (exon 19 deletion, L858R, L861Q, G719X) Perioperative cytotoxic chemotherapy and radiation therapy as indicated Stratify by stage and perioperative chemotherapy N=286 Adjuvant erlotinib up to 24 months with CT chest every 6 months, then yearly N=190 CT chest every 6 months for 24 months, then yearly N=96 CT scan at 30 months Follow patients for recurrence and death. Patients with recurrence will be biopsied to confirm recurrence and test for molecular determinants of acquired resistance Record subsequent chemotherapies.
27 EURECA: Trial Design Innovations Primary Endpoint: Pathologic Documentation of Recurrence Internet-Based Data Collection No pathology review needed mutation presence only required No scan data collection needed No blood testing needed
28 Adjuvant Chemotherapy for NSCLCs ELIGIBLE: N = 945 Resected I-IIIA ( lobectomy) IHC/FISH for EGFR required Ongoing Trials: RADIANT Adjuvant Chemotherapy allowed STRATIFIED: Histology Gender Age EGFR Status Smoking Adj Chemo R A N D O M I Z E 2:1 Erlotinib 150 mg po qd x 2 years Observation DFS as primary endpoint Completed Sep 09 NCT
29 Adjuvant Chemotherapy for NSCLCs Ongoing Trials: The MAGRIT study of GSK A Antigen-Specific Immunotherapeutic Product ELIGIBLE: N = 2270 Resected IB-IIIA ( lobectomy) Tumor MAGE-A3 gene expression No prior chemo No RT R A N D O M I Z E Other adjuvant therapy not defined in trial registry GSK A 13 injections over 27 months Placebo 13 injections over 27 months MAGE-A3 (Melanoma AntiGEn-A3) is expressed by many tumors but not normal tissues. Primary endpoint = DFS NCT
30 E1505: Phase 3 Adjuvant Chemotherapy Bevacizumab Resected IB (>4cm) IIIA Adequate MLND sampling All pts: level 7 Left: level 5 or 6 Right: level 4 N = 1500 R A N D O Chemotherapy* x 4 cycles Closed to accrual M 7 October 2013 I Z Chemotherapy* x 4 cycles + E bevacizumab x 1 year Cisplatin and vinorelbine Cisplatin and docetaxel Cisplatin and gemcitabine Cisplatin and pemetrexed Primary endpoint: overall survival Interim results anticipated in 2016
31 Adjuvant Afatinib: 3 months vs 2 years Lecia Sequist, PI Resected Stage I-III EGFR+ lung cancer s/p completion of standard adjuvant chemotherapy +/-RT Baseline CT NED R A N D O M I Z E Afatinib oral daily x 3 months CT chest every 6 months x 3 years and then annually Afatinib oral daily x 2 years RFS at 5 years 92 patients will be stratified for pathologic stage (I, II, III) powered to detect a recurrence free survival improvement of 20%
32 Proposed ALCEMIST Schema Register post-op Register pre-op ALCEMIST Trial Assess & obtain FFPE tissue SOP for FFPE tissue Collect blood; Central EGFR & ALK genotyping Patients on adjuvant trials followed separately Follow q6 months for 5 years Optional fresh/ frozen tissue FFPE tissue & blood specimen FFPE tissue from recurrence biopsy Advanced genomics at the NCI Center for Cancer Genomics patients will be screened over 4-5 years
33 ALCHEMIST-Related Adjuvant Trials Alliance A Govindin Stage IB- IIIA NSCLC Complete Surgical Resection Screen for EGFR mutation+ cancers Adjuvant Therapy (if indicated) R a n d o m i z e Erlotinib X 2 years Placebo ECOG E4517 Ramalingam Stage IB- IIIA NSCLC Complete Surgical Resection Screen for ALK+ cancers Adjuvant Therapy (if indicated) R a n d o m i z e Crizotinib X 2 years Placebo
34 LCMC: Oncogenic Drivers Detected in 63% of Patients With Lung Adenocarcinomas Kris Proc WCLC 2013
35 Use of Molecular Characteristics to Select Available Adjuvant Therapies for Patients With Lung Cancers
36 Induction (Neoadjuvant) vs Adjuvant Factors Favoring Induction Chemotherapy Attacks micrometastases at earliest time Better drug delivery and tolerability Ability to assess sensitivity of agents used in induction and planned for adjuvant Platform for new agent testing Surgical findings an outcome surrogate Time to identify unsuspected metastases and comorbidities before local therapy Randomized trials equivalent or better Provides quicker answers
37 In breast cancers, trials using pathologic complete response (pcr) after induction yields quicker results Trial Intervention Outcome measured Time from enrollment to publication of data NSABP B-18 Surg Chemo Vs Chemo Surg Overall Survival 10 years NSABP B-27 Buzdar et al NSABP B-40 GBG44 NeoSphere AC Surg Doce Vs AC Doce Surg Chemo Surg Vs Chemo + Tras Surg Chemo Surg Vs Chemo + Bev Surg Chemo Surg Vs Chemo + Bev Surg Chemo+Tras Surg VS Chemo+Tras+Pertuzumab Surg Overall Survival pcr pcr pcr pcr pcr 11 years 8 years 4 years 5 years 5 years 4 years Fisher B et al, JCO 1998 Bear HD et al, JCO 2006 Bear HD et al, JCO 2003 Buzdar et al, JCO 2005 Bear HD et al, NEJM 2010 Von Minckwitz G et al, NEJM 2010 Gianni L et al, Lancet Oncol 2012 FIRST therapy to be approved by FDA based on path CR
38 P e rc e n t s u rv iv a l We can do it too Major pathologic response (mpr) correlates with overall survival in patients with lung cancers MD Anderson all stages MSKCC stage IIIA only O v e r a ll S u r v iv a l < /= 1 0 % re s id u a l tu m o r (n = 1 2 ) 5 0 A ll o th e rs (n = ) S u rv iv a l (m o n th s ) Pataer et al, JTO 2012 Hellmann Lancet Oncology (in press) Chaft IASLC WCLC 2013 Hellmann IASLC WCLC 2013
39 Bending the survival curve in lung cancers Stage IV EGFR-mutant Lung cancers - Today Stages I - III EGFR-mutant Lung cancers - Tomorrow Rudin Proc IASLC 2013
40 New Directions for Adjuvant Therapies of Lung Cancers Conclusions All patients with lung cancers need adjuvant therapies Data demonstrates practicality, safety, and disease free survival benefit for adjuvant TKI use in EGFR mutant lung cancers, likely survival benefit as well GIST data shows survival benefit. Longer duration better Multiplex testing finds an actionable target in 63% While both induction and adjuvant therapies are effective, induction has many advantages The time is now to use and test therapies directed against oncogenic drivers: EGFR, ALK and others too! It s good to go molecular. Let s bend the curve.
41
42 Bending the survival curve in lung cancers Rudin Proc IASLC 2013
43 Bending the survival curve in lung cancers Stage IV EGFR-mutant Lung cancers Rudin Proc IASLC 2013
44 ALCHEMIST: Linked Trials E4512 A Target ALK+ EGFR mutation + Agent Crizotinib Erlotinib n Primary Endpoint DFS OS Power 80% 85% One-sided α HR Correlative Studies Peripheral screening for ALK; RTPCR to identify fusion partners Targeted sequence and kinome analysis; PRO and QOL
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationALCHEMIST. Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials
ALCHEMIST Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials What is ALCHEMIST? ALCHEMIST is 3 integrated trials testing targeted therapy in early stage lung cancer: l A151216:
More informationState of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD
State of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD Professor and Chair Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Nothing to disclose DISCLOSURE Objectives Lung
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationTargeted therapies for advanced non-small cell lung cancer. Tom Stinchcombe Duke Cancer Insitute
Targeted therapies for advanced non-small cell lung cancer Tom Stinchcombe Duke Cancer Insitute Topics ALK rearranged NSCLC ROS1 rearranged NSCLC EGFR mutation: exon 19/exon 21 L858R and uncommon mutations
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationLeading the Way to Precision Care: Molecular Diagnostics and Therapeutics in Lung Cancers. Mark G Kris, MD Memorial Sloan Kettering New Amsterdam USA
Leading the Way to Precision Care: Molecular Diagnostics and Therapeutics in Lung Cancers Mark G Kris, MD Memorial Sloan Kettering New Amsterdam USA Molecular Therapeutics in Lung Cancers Financial Disclosures
More informationDisclosure of Relevant Financial Relationships NON-SMALL CELL LUNG CANCER: 70% PRESENT IN ADVANCED STAGE
MORPHOLOGY AND MOLECULAR TESTING IN NON-SMALL CELL OF LUNG NEW FRONTIEIRS IN CYTOPATHOLOGY PRACTICE American Society for Cytopathology San Antonio, Texas Sunday March 5, 2017 Disclosure of Relevant Financial
More informationLung Cancer Update 2016 BAONS Oncology Care Update
Lung Cancer Update 2016 BAONS Oncology Care Update Matthew Gubens, MD, MS Assistant Professor Chair, Thoracic Oncology Site Committee UCSF Helen Diller Family Comprehensive Cancer Center Disclosures Consulting
More informationMolecular Testing in Lung Cancer
Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans
More informationHeather Wakelee, M.D.
Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Sponsored by Educational Grant Support from Adjuvant (Post-Operative) Lung Cancer Chemotherapy Heather Wakelee, M.D.
More informationLung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17
Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD Mount Carrigain 2/4/17 Histology Adenocarcinoma: Mixed subtype, acinar, papillary, solid, micropapillary, lepidic
More informationHOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY
HOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY 7 TH Annual New York Lung Cancer Symposium Saturday, November 10, 2012 William D. Travis, M.D. Attending Thoracic Pathologist Memorial Sloan Kettering
More informationTargeted Therapies for Advanced NSCLC
Targeted Therapies for Advanced NSCLC Current Clinical Developments Friday, June 3, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016 ASCO Annual Meeting
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationSupplementary Online Content
Supplementary Online Content Kris MG, Johnson BE, Berry LD, et al. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. JAMA. doi:10.1001/jama.2014.3741 etable 1. Trials
More informationSystemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know)
Systemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know) นายแพทย ช ยย ทธ ย ทธ เจร ญธรรม หน วยมะเร งว ทยา ภาคว ชาอาย ร อาย รศาสตร Inter-hospitol Conference, 16 th March 2013 Systemic
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationLung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationOTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento
OTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento Dolores Isla Servicio de Oncología Médica HCU Lozano Besa de Zaragoza 2008 Selection Factors in Advanced NSCLC ( 8y ago)
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationPIK3CA mutations are found in approximately 7% of
Original Article Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas Juliana Eng, MD,*
More informationOptimal Application of Adjuvant Therapy in NSCLC
Optimal Application of Adjuvant Therapy in NSCLC Heather Wakelee, MD Stanford University, Stanford Cancer Institute Post 1995 Meta-Analysis : NSCLC Randomized Adjuvant Platinum Trials Trial Stage n Chemo
More informationSlide 1. Slide 2 Post 1995 Meta-Analysis : Slide 3
Slide 1 Optimal Application of Adjuvant Therapy in NSCLC Heather Wakelee, MD Stanford University, Stanford Cancer Institute Slide 2 Post 1995 Meta-Analysis : NSCLC Randomized Adjuvant Platinum Trials Trial
More informationInhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS
Inhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS Driver Mutations to Classify Lung Cancer Unknown 36% KRAS 25% EGFR 15% ALK 4% HER2 2% Double Mut 2% BRAF 2% PIK3CA
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationK-Ras signalling in NSCLC
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationManagement of advanced non small cell lung cancer
Management of advanced non small cell lung cancer Jean-Paul Sculier Intensive Care & Thoracic Oncology Institut Jules Bordet Université Libre de Bruxelles (ULB) www.pneumocancero.com Declaration No conflict
More informationManagement Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors
Management Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors Conor E. Steuer, MD Assistant Professor The Winship Cancer Institute of Emory University July 27, 2017 1 Lung Cancer One
More informationSystemic therapy in early stage NSCLC. Disclosures
Systemic therapy in early stage NSCLC Christian Manegold, MD Professor of Medicine, Heidelberg University Interdisciplinary Thoracic Oncology Department of Surgery University Medical Center Mannheim, Germany
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationBiomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
More informationOptimum Sequencing of EGFR targeted therapy in NSCLC. Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey
Optimum Sequencing of EGFR targeted therapy in NSCLC Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey Lung cancer NSCLC SCLC adeno squamous EGFR ALK ROS1 BRAF HER2 KRAS EGFR Transl Lung Cancer
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationSlide 1. Slide 2. Slide 3. Disclosures. Personalized Medicine for Advanced NSCLC in East Asia. No conflicts related to this presentation
Slide 1 12 th International Lung Cancer Conference Personalized Medicine for Advanced NSCLC in East Asia Masahiro Tsuboi, M.D., Ph.D. Group Chair, Lung Cancer Surgical Study Group in Japan Clinical Oncology
More informationEGFR Mutation-Positive Acquired Resistance: Dominance of T790M
Treatment of EGFR Mutation-Positive Acquired Resistance: T790M+ or T790M- H. Jack West, MD Swedish Cancer Institute, Seattle, WA EGFR Mutation-Positive Acquired Resistance: Dominance of T790M Yu, Clin
More informationPrognostic and predictive biomarkers in
OLOGICAL SCIENCES O DEPT. OF CLINICAL & BIO UNIVERSITY UNIVERSTY OF TORINO Prognostic and predictive biomarkers in early stage NSCLC Giorgio V. Scagliotti University of Torino Department of Clinical &
More informationTargeted Therapy for NSCLC: EGFR and ALK Fadlo R. Khuri, MD
EGFR and ALK Fadlo R. Khuri, MD President, American University of Beirut Professor of Medicine July 26, 2018 A great year end! Targeted Therapy for NSCLC: Evolving Landscape of Lung Adenocarcinoma NSCLC
More informationEstado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico
Estado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico Enriqueta Felip Vall d Hebron University Hospital Barcelona, Spain Stage I-II
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationNeoadjuvantTreatment In BC When, How, Who?
NeoadjuvantTreatment In BC When, How, Who? Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service, MSKCC Professor of Medicine, Weill Cornell Medical College President, ASCO 15 Potential Benefits Of
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationQuale sequenza terapeutica nella malattia EGFR+
Trattamento della malattia avanzata oncogene-addicted Quale sequenza terapeutica nella malattia EGFR+ Chiara Bennati AUSL della Romagna Ravenna, Italy A matter of fact Outline Can we improve PFS/OS with
More informationPersonalized Medicine for Advanced NSCLC in East Asia
Personalized Medicine for Advanced NSCLC in East Asia - Update treatment strategy for NSCLC based on Japanese clinical practice guideline - Masahiro Tsuboi, M.D., Ph.D. Associate-professor, School of Medicine,
More informationThe most effective treatment for lung adenocarcinoma is
ORIGINAL ARTICLE Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations Yelena Y. Janjigian, MD,* Bernard J. Park,
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationDesign considerations for Phase II trials incorporating biomarkers
Design considerations for Phase II trials incorporating biomarkers Sumithra J. Mandrekar Professor of Biostatistics, Mayo Clinic Pre-Meeting Workshop Enhancing the Design and Conduct of Phase II Studies
More informationThe discovery of targetable driver mutations in a subset of
Original Article Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers Anya M. Litvak, MD,* Paul K. Paik, MD,* Kaitlin M. Woo, MS, Camelia S. Sima, MD, Matthew D. Hellmann, MD,*
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationCombined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationDesigning a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials
Review Article Page 1 of 8 Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials Ryan S. Alden 1, Sumithra J. Mandrekar 2, Geoffrey R. Oxnard
More informationPersonalized Treatment Approaches for Lung Cancer
Personalized Treatment Approaches for Lung Cancer California Thoracic Society 2018 Annual Carmel Conference January 27, 2018 Matthew Gubens, MD, MS Associate Professor of Medicine Chair, Thoracic Oncology
More information8/8/2011. PONDERing the Need to TAILOR Adjuvant Chemotherapy in ER+ Node Positive Breast Cancer. Overview
Overview PONDERing the Need to TAILOR Adjuvant in ER+ Node Positive Breast Cancer Jennifer K. Litton, M.D. Assistant Professor The University of Texas M. D. Anderson Cancer Center Using multigene assay
More informationNCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018
Guideline Page and Request Illumina Inc. requesting to replace Testing should be conducted as part of broad molecular profiling with Consider NGS-based assays that include EGFR, ALK, ROS1, and BRAF as
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More informationTargeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont. Masterclass 27 september 2018
Targeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont Masterclass 27 september 2018 Outline Introduction EGFR TKI ALK TKI TKI for uncommon driver mutations Take home messages The promise of
More informationAdjuvant treatment for EGFR-mutated non-small cell lung cancer: do we have a major breakthrough?
Editorial Adjuvant treatment for EGFR-mutated non-small cell lung cancer: do we have a major breakthrough? Giandomenico Roviello 1, Marco Imperatori 1, Michele Aieta 1, Francesco Sollitto 2, Matteo Landriscina
More informationIs the Neo-adjuvant Approach Better than Adjuvant Approach? Comparative Levels of Evidence: Randomized Trials
Is the Neo-adjuvant Approach Better than Approach? Virginie Westeel University Hospital Besançon, France Perspectives in Lung Cancer Amsterdam, 5-6 March 2010 Comparative Levels of Evidence: Randomized
More informationCooperative Group Update - Japan; JCOG & WJOG -
Cooperative Group Update - Japan; JCOG & WJOG - Masahiro Tsuboi, M.D., Ph.D. Associate-professor, School of Medicine, Yokohama City University Chief, Division of Thoracic Surgery, Respiratory Disease Center
More informationDo You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement. Reference Slides Introduction
Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement Reference Slides Introduction EML4-ALK Fusion Oncogene Key Driver in 3% to 7% NSCLC Inversion or Translocation
More informationSecond-line treatment for advanced NSCLC
UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Life was so simple back in 2008 Di
More informationOncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
More informationTriple Negative Breast cancer New treatment options arenowhere?
Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no
More informationPersonalized Medicine: Lung Biopsy and Tumor
Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Elizabeth H. Moore, MD Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Genomic testing has resulted in a paradigm shift in the
More informationWhy Do Axillary Dissection? Nodal Treatment and Survival NSABP B04. Revisiting Axillary Dissection for SN Positive Patients
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA Why Do Axillary Dissection? 6 August 2011 Implications
More informationDr. Andres Wiernik. Lung Cancer
Dr. Andres Wiernik Lung Cancer Lung Cancer Facts - Demographics World Incidence: 1 8 million / year World Mortality: 1 6 million / year 5-year survival rates vary from 4 17% depending on stage and regional
More informationWhich Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy
Which Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy Joseph Chao, M.D. Assistant Clinical Professor Department of Medical Oncology & Therapeutics
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationEsophageal and GEJ Adenocarcinoma: Chemo + RT is the Preferred Treatment
Esophageal and GEJ Adenocarcinoma: Chemo + RT is the Preferred Treatment David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan-Kettering Cancer Center Preop Therapy in Esophageal and
More informationReliable Evaluation of Prognostic & Predictive Genomic Tests
Reliable Evaluation of Prognostic & Predictive Genomic Tests Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute http://brb.nci.nih.gov Different Kinds of Biomarkers Prognostic
More informationDebate on stage III NSCLC: The role of systemic therapy
1 Debate on stage III NSCLC: The role of systemic therapy Rolf Stahel University Hospital of Zürich Bucharest, 16.6..2015 2 Stage III disease: The problem of heterogeneity, the risk of distant metastases
More informationD Ross Camidge, MD, PhD
i n t e r v i e w D Ross Camidge, MD, PhD Dr Camidge is Director of the Thoracic Oncology Clinical Program and Associate Director for Clinical Research at the University of Colorado Cancer Center in Aurora,
More informationImplications of ACOSOG Z11 for Clinical Practice: Surgical Perspective
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA 6 August 2011 Implications of ACOSOG Z11 for Clinical
More informationNeoadjuvant Treatment of. of Radiotherapy
Neoadjuvant Treatment of Breast Cancer: Role of Radiotherapy Neoadjuvant Chemotherapy Many new questions for radiation oncology? lack of path stage to guide indications should treatment response affect
More informationBest of ASCO 2014 Lung
Best of ASCO 214 Lung Heather Wakelee, MD Associate Professor of Medicine, Oncology Stanford Cancer Institute Stanford, California USA Outline ALK: 82: 1st line crizotinib Profile 114 83: ASCEND ceritinib
More informationBrain metastases and meningitis carcinomatosa: Prof. Rafal Dziadziuszko Medical University of Gdańsk, Poland
Brain metastases and meningitis carcinomatosa: a palliative situation? Prof. Rafal Dziadziuszko Medical University of Gdańsk, Poland SAMO, Lucerne, February 1-2, 2013 Treatment options for NSCLC patients
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationMutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma
Cancer Medicine ORIGINAL RESEARCH Open Access Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma Zhengbo Song 1,2, Xinmin Yu 1 & Yiping Zhang 1,2 1 Department
More informationTreatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line
Treatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line Martin Reck David F. Heigener Department of Thoracic Oncology Hospital Grosshansdorf Germany Identification of driver mutation in tumor specimens
More information非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和
資料 2 2 非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和 1 Preclinical studies Therapeutic Window: Efficacy/Toxicity Disease Specificity Subtype Specificity Combination: Concurrent/Sequential Therapeutic situation: Response/
More informationRTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman
RTOG Lung Cancer Committee 2012 Clinical Trial Update Wally Curran RTOG Group Chairman 1 RTOG Lung Committee: Active Trials Small Cell Lung Cancer Limited Stage (Intergroup Trial) Extensive Stage (RTOG
More informationChanging demographics of smoking and its effects during therapy
Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More informationErlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy
Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy September 2008 This technology summary is based on information available at the time of research and a
More information